Clinical significance of the physicochemical properties of LDL in type 2 diabetes

被引:18
作者
Scheffer, PG
Teerlink, T
Heine, RJ
机构
[1] VU Univ, Med Ctr, Dept Clin Chem, NL-1007 MB Amsterdam, Netherlands
[2] VU Univ, Med Ctr, Dept Endocrinol, Amsterdam, Netherlands
[3] VU Univ, Med Ctr, Cardiovasc Res Inst, Amsterdam, Netherlands
关键词
atherosclerosis; diabetes; LDL; LDL diameter; LDL glycation; LDL oxidation; LDL size;
D O I
10.1007/s00125-005-1736-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherosclerosis is the leading cause of death in type 2 diabetes. LDL cholesterol and atherosclerosis are related, both in healthy people and those with diabetes; however, people with diabetes are more prone to atheroma, even though their LDL cholesterol levels are similar to those in their non-diabetic peers. This is because LDL particles are modified in the presence of diabetes to become more atherogenic. These modifications include glycation in response to high plasma glucose levels; oxidative reactions mediated by increased oxidative stress; and transfer of cholesterol ester, which makes the particles smaller and denser. The latter modification is strongly associated with hypertriglyceridaemia. Oxidatively and non-oxidatively modified LDL is involved in plaque formation, and may thus contribute to the accelerated atherosclerosis. This review discusses the techniques currently used to determine the physicochemical properties of LDL, and examines the evidence that modification of these properties plays a role in the accelerated atherosclerosis associated with type 2 diabetes.
引用
收藏
页码:808 / 816
页数:9
相关论文
共 88 条
[1]   Baseline diene conjugation in LDL lipids as a direct measure of in vivo LDL oxidation [J].
Ahotupa, M ;
Marniemi, J ;
Lehtimäki, T ;
Talvinen, K ;
Raitakari, OT ;
Vasankari, T ;
Viikari, J ;
Luoma, J ;
Ylä-Herttuala, S .
CLINICAL BIOCHEMISTRY, 1998, 31 (04) :257-261
[2]   Leukocyte lipid peroxidation, superoxide dismutase, glutathione peroxidase and serum and leukocyte vitamin C levels of patients with type II diabetes mellitus [J].
Akkus, I ;
Kalak, S ;
Vural, H ;
Caglayan, O ;
Menekse, E ;
Can, G ;
Durmus, B .
CLINICA CHIMICA ACTA, 1996, 244 (02) :221-227
[3]   Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans [J].
Anber, V ;
Griffin, BA ;
McConnell, M ;
Packard, CJ ;
Shepherd, J .
ATHEROSCLEROSIS, 1996, 124 (02) :261-271
[4]   PROSPECTIVE-STUDY OF SMALL LDLS AS A RISK FACTOR FOR NON-INSULIN-DEPENDENT DIABETES-MELLITUS IN ELDERLY MEN AND WOMEN [J].
AUSTIN, MA ;
MYKKANEN, L ;
KUUSISTO, J ;
EDWARDS, KL ;
NELSON, C ;
HAFFNER, SM ;
PYORALA, K ;
LAAKSO, M .
CIRCULATION, 1995, 92 (07) :1770-1778
[5]   AUTOANTIBODIES AGAINST OXIDATIVELY MODIFIED LOW-DENSITY LIPOPROTEINS IN NIDDM [J].
BELLOMO, G ;
MAGGI, E ;
POLI, M ;
AGOSTA, FG ;
BOLLATI, P ;
FINARDI, G .
DIABETES, 1995, 44 (01) :60-66
[6]   Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system [J].
Bjornheden, T ;
Babyi, A ;
Bondjers, G ;
Wiklund, O .
ATHEROSCLEROSIS, 1996, 123 (1-2) :43-56
[7]   Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women [J].
Blake, GJ ;
Otvos, JD ;
Rifai, N ;
Ridker, PM .
CIRCULATION, 2002, 106 (15) :1930-1937
[8]   Heritability of LDL peak particle diameter in the Quebec family study [J].
Bossé, Y ;
Vohl, MC ;
Després, JP ;
Lamarche, B ;
Rice, T ;
Rao, DC ;
Bouchard, C ;
Pérusse, L .
GENETIC EPIDEMIOLOGY, 2003, 25 (04) :375-381
[9]   GLYCOSYLATED LOW-DENSITY-LIPOPROTEIN IS MORE SENSITIVE TO OXIDATION - IMPLICATIONS FOR THE DIABETIC PATIENT [J].
BOWIE, A ;
OWENS, D ;
COLLINS, P ;
JOHNSON, A ;
TOMKIN, GH .
ATHEROSCLEROSIS, 1993, 102 (01) :63-67
[10]   Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus [J].
Brunzell, JD ;
Ayyobi, AF .
AMERICAN JOURNAL OF MEDICINE, 2003, 115 :24-28